| HOME >> BIOLOGY >> TECHNOLOGY |
Acquisition of property,
plant and equipment (1,229,151) (379,392) (2,236,575) (257,280)
Net cash used in
investing activities (293,386) (376,006) (2,671,496) (234,554)
Exchange effect on cash
and equivalents 119,919 99,013 542,189 155,557
Increase (decrease) in
cash and cash
equivalents (1,758,441)(2,369,553) 1,748,774 33,537
Cash and cash
equivalents,
beginning of period 20,578,712 6,912,816 17,071,497 9,248,832
Cash and cash
equivalents,
end of period $18,820,271 $9,282,369 $18,820,271 $9,282,369
Cash paid for
interest, net
of interest
capitalized $133,612 $71,816 $306,005 $159,818
Cash paid for income
taxes $871,557 $416,330 $1,309,963 $517,674
Supplemental schedule of
non-cash activities:
Acquisition of property,
plant and equipment
Included in accounts
payable and accrued
liabilities $ -- $ -- $546,514 $74,718
For more information, please contact:
Contact Information: Investors/Media:
Helen G. Yang Stephanie Carrington/Janine McCargo
Sinovac Biotech Ltd. The Ruth Group
Tel: +86-10-8289-0088 x871 Tel: +1-646-536-7017/7033
Fax: +86-10-6296-6910 Email: scarrington@theruthgroup.com
Email: info@sinovac.com jmccargo@theruthgroup.com
| SOURCE Sinovac Biotech Ltd. Copyright©2008 PR Newswire. All rights reserved |